D-0135-2017 Class III Terminated
FDA drug recall D-0135-2017 was initiated by Mylan Institutional, Inc. (D.B.A. UDL Laboratories) on Sep 28, 2016 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: out of specification result for Clonazepam Related Compound (RC) A (a known impurity) at 15 month timepoint. The recall status is terminated (terminated Aug 28, 2018). Affected quantity: 1,182 unit dose cards of 300 (10 punch cards of 30 tablets each) and 52,618 unit dose blister cards (10 cards of 10…
Recall details
- Product Type
- Drugs
- Report Date
- Nov 16, 2016
- Initiation Date
- Sep 28, 2016
- Termination Date
- Aug 28, 2018
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1,182 unit dose cards of 300 (10 punch cards of 30 tablets each) and 52,618 unit dose blister cards (10 cards of 10 tablets each)
Product description
Clonazepam Tablets, USP, 0.5 mg, packaged in a)100- count unit dose box of 10 x 10 blister cards (NDC 51079-881-20) and b) 300-count unit dose box of 10 x 30 punch cards (NDC 51079-881-56), Rx only, Manufactured by Mylan Pharmaceuticals Inc, Morgantown, WV, 26505
Reason for recall
Failed Impurities/Degradation Specifications: out of specification result for Clonazepam Related Compound (RC) A (a known impurity) at 15 month timepoint.
Distribution pattern
Nationwide
Code information
Lot#: a) 3061779, Exp 11/16; 3071447, Exp 04/17; b)3071789, Exp 04/17
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0135-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026